No Data
Buy Rating for Silence Therapeutics: Promising Phase 1 Results and Future Prospects
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely
Express News | Silence Therapeutics - From Time to Time, Co or Any Selling Shareholder May Offer and Sell Ordinary Shares
Express News | Silence Therapeutics PLC Files for Stock Shelf; Size Not Disclosed - SEC Filing
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
AstraZeneca Deal Has Positive Read for Silence Therapeutics, Says Morgan Stanley
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is LackingNo Data
No Data
